Digitek

Little Rock, Arkansas

On April 25, 2008, Actavis Totowa LLC, a generic pharmaceutical manufacturer, announced a nationwide recall of Digitek® tablets. The recall includes all tablets distributed and available for commercial sale as of April 25. The purpose of the recall is to protect consumers from potential serious injury or death as a result of taking the Digitek tablets. It has been determined that there is a possibility that Digitek tablets with double the appropriate thickness, and twice the approved level of digoxin, may have been commercially released.

The tablets in question were distributed by Mylan Pharmaceuticals, Inc., under the Bertek and UDL Laboratories, Inc. labels. The scope of the problem has not fully been determined, but there is evidence to suggest that the manufacturing problems leading to the April 25 recall may have been present as early as 2006.

Digitek tablets contain the active ingredient digoxin, a drug commonly used for the treatment of heart failure and certain types of abnormal heart rhythms. While generally safe at the appropriate dose, toxicity can result from higher-than-normal doses of digoxin, which can lead to serious injury or death. Digoxin toxicity can lead to chronic conditions resulting in slow heart rate, rapid heart beat, atrioventricular block, dysrhythmia, and chronic low blood pressure. Digoxin toxicity can also lead to cardiac instability, cardiac arrest and death.

Due to the potential severity of the Digitek tablets recall, patients currently taking Digitek tablets are advised to contact their prescribing physician as soon as possible to advise of potential exposure to the recalled product and to contact the pharmacy where they obtained their prescription to obtain a suitable replacement for their digoxin therapy.

If you or a loved one have experienced adverse effects related to the use of Digitek tablets, you should contact us immediately. The attorneys at Duncan Firm will confidentially review your case at no cost and advise you of your legal rights.